

Press Release

ProStrakan Group plc

ProStrakan Appointment of New Chief Financial Officer

Galashiels, Scotland, 17th April 2007 - ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, announces today that it has appointed Paul Garvey as Chief Financial Officer, replacing Adrian Gardner.

Paul is a Chartered Accountant and has over 25 years experience in senior finance positions, including most recently being Group Finance Director of Axis-Shield plc, based in Scotland. Adrian will remain with the company in the coming months to ensure adequate handover, and to complete certain ongoing projects.

Commenting on the changes, **Dr Wilson Totten, CEO of ProStrakan**, said: "I am delighted to appoint Paul into this pivotal role. His experience and strengths will be key assets in continuing the growth of the business. Adrian has been a key part of building ProStrakan into its current position of financial strength, and he carries the full support of the Board as he moves towards the next phase of his career."

With reference to paragraphs 9.6.13 (1)-(6) of the FSA's listing rules, Paul is also non-executive director of Inion Oy. There are no other disclosures required.

For more information, please contact:

ProStrakan

Wilson Totten, CEO

Callum Spreng, Corporate Communications Director +44 (0)1896 664000

Financial Dynamics

David Yates / Anna Keeble

+44 (0)20 7831 3113

Notes to Editors

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The Company's Development facilities are situated at the Company's Headquarters in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries based in the UK, France, Germany, Spain and other EU countries.

www.prostrakan.com